HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Limiting Reproductive Rights Has US Consumers Searching For OTC Access To Birth Control

Executive Summary

Fractl looked into online OTC birth control searches for HBW Insight after initially focusing on interest in male birth control options since the Supreme Court’s ruling in Dobbs vs. Jackson.

You may also be interested in...



Perrigo Delivers ‘Remarkable Quarter’ As OTC Birth Control Waits In Wings

Perrigo delivered second-quarter results which CEO Murray Kessler described as “truly remarkable” as it lined up its oral contraceptive Opill (0.075-mg norgestrel) for OTC designation.

Survey Shows US Voters Have Message For FDA And Congress About OTC Birth Control

Data For Progress survey of 1,252 likely voters found “overwhelmingly support” from Democrats and Republicans for women’s access to daily oral contraceptives without a prescription and for FDA to allow OTC access.

US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups

CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel